Answer Found in the 'NG Scene' of the DNA Blueprint: Discovery of Antigens for a Personalized mRNA Vaccine for Rectal Cancer
1. Why are cancer mRNA vaccines more challenging than COVID‑19 vaccines?
COVID‑19 vaccines had a clear target—the spike protein—whereas cancer cells differ from patient to patient and across tumor types. In particular, accurately predicting tumor antigens and eliciting robust immune responses is difficult, requiring a precision akin to crafting a unique key for each of millions of locks.
2. Alternative Splicing: Tracing Editing Errors in the Genetic Blueprint
The process by which cells select the necessary portions of the DNA blueprint to produce proteins is called splicing. The research team analyzed rectal cancer patient data (TCGA‑READ) and identified alternative splicing patterns that are unusually frequent in cancer cells.
Exon skipping—the loss of exon fragments of genetic information—was the most commonly observed event. By intersecting frameshift mutations arising from this editing process with the affected genes, the team pinpointed 217 genes as the “best license plates” for identifying cancer cells, i.e., potential antigen candidates.
3. Designing a ‘Custom Vaccine’ Tailored to Individual Immune Maps
Even the most promising antigen is ineffective if the patient’s immune milieu is not primed to recognize it. The researchers compared the identified antigens with each patient’s immune subtype. In certain immune subtypes, the antigens were more prominently presented, and cytotoxic T cells infiltrated the tumor more efficiently. Consequently, a one‑size‑fits‑all vaccine is no longer required; a personalized mRNA vaccine that incorporates both genetic and immunologic characteristics of each patient can now be designed.
4. Implications and Outlook: A Concrete Step Toward Curative Rectal Cancer Therapy
This study goes beyond antigen discovery by establishing criteria to predict which patients will benefit most and how the vaccine should be administered in clinical settings. If this strategy advances through clinical trials and reaches commercialization, rectal cancer patients could receive a low‑toxicity, highly potent “personalized weapon” that selectively eradicates their own tumor cells.
BACKGROUND: mRNA vaccines have emerged as a promising platform for cancer immunotherapy, particularly following the success of COVID-19 vaccines. However, the development of cancer vaccines presents challenges such as difficulties in antigen prediction and poor immunogenicity, especially in identifying and delivering highly immunogenic tumor-specific antigens. The variability and low immunogenicity of tumor antigens further complicates this process. METHODS: This study utilized public data and bioinformatics analysis to identify potential tumor antigens in cancer and characterize different immune subtypes. This approach aims to guide the development of cancer mRNA vaccines with enhanced immune response. RESULTS: In the cancer genome atlas rectal adenocarcinoma(TCGA-READ), Exon skipping was the most common alternative splicing event in TCGA-READ, whereas mutually exclusive exons were the least common. We identified 4480 upregulated and 3328 downregulated AS events, with missense mutations being the most frequent. A total of 217 potential antigen genes were identified by intersecting upregulated AS anomalies and frameshift mutations. CONCLUSIONS:
It is a technology that exploits the ‘disguise’ (splicing variation) hidden by cancer cells to expose their identity. By embedding patient‑specific tumor features into a vaccine, it maximizes the host immune response, allowing rectal cancer patients to reduce the burden of conventional therapy and move a step closer to cure.